| Literature DB >> 34743418 |
Kohei Saito1,2,3, Tatsuhide Inoue1, Hiroyuki Ariyasu1, Toshio Shimada3, Hiroshi Itoh2, Issei Tanaka1, Chikashi Terao3,4,5.
Abstract
AIMS/Entities:
Keywords: Homeostasis model assessment; Type 1 diabetes; Type 2 diabetes
Mesh:
Substances:
Year: 2021 PMID: 34743418 PMCID: PMC9017630 DOI: 10.1111/jdi.13707
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 3.681
Participants’ characteristics
| Item | Values |
|---|---|
| No. participants | 651 |
| Sex, female (%) | 233 (35.8) |
| Age at admission (years) | 63.0 [51.0–72.0] |
| BMI (kg/m2) | 24.3 [21.4–27.4] |
| HbA1c (%) | 10.5 [9.1–12.4] |
| FBG (mg/dL) | 160 [131–204] |
| CPR (pg/mL) | 1.7 [1.0–2.4] |
| HOMA2‐B (%) | 37.2 [23.1–57.1] |
| HOMA2‐IR | 1.5 [0.9–2.2] |
| Hemoglobin (g/dL) | 14.0 [12.8–15.2] |
| MCV (fL) | 89.0 [86.0–92.0] |
| AST (IU/L) | 20.0 [16.0–29.0] |
| ALT (IU/L) | 21.0 [15.0–34.0] |
| γGTP (IU/L) | 29.0 [19.0–54.0] |
| eGFR (mL/min/1.73 m2) | 81.0 [60.5–99.0] |
| Creatinine (mg/dL) | 0.7 [0.6–0.9] |
| HDL‐c (mg/dL) | 45.0 [39.0–57.0] |
| LDL‐c (mg/dL) | 114 [90.0–138] |
| Triglyceride (mg/dL) | 124 [87.0–180] |
| Urinary albumin excretion (g/day) | 11.8 [5.6–47.9] |
| eGFR <60 mL/min/1.73 m2 (%) | 153 (24.1) |
| eGFR < 45 mL/min/1.73m2 (%) | 68 (10.7) |
| Treatment | |
| Metformin (%) | 216 (33.2) |
| Thiazolidinediones (%) | 8 (1.2) |
| Sulfonylurea (%) | 46 (7.1) |
| Glinides (%) | 119 (18.3) |
| Alpha‐glucosidase inhibitors (%) | 98 (15.1) |
| SGLT2 inhibitors (%) | 85 (13.1) |
| DPP4 inhibitors (%) | 304 (46.7) |
| GLP‐1 receptor agonists (%) | 135 (20.7) |
| Insulin injections (%) | 528 (81.1) |
| Statins (%) | 232 (35.6) |
Data presented as n (%) or n [interquartile range]. γGTP, γ‐glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CPR, C‐peptide immunoreactivity; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; GLP‐1, glucagon‐like peptide‐1; HbA1c, hemoglobin A1c; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol, MCV; mean cell volume; SGLT2, sodium–glucose co‐transporter 2.
Figure 1Distributions of the five clusters and clinical characteristics of each cluster (n = 651). The cluster analysis was carried out separately for men and women, and then combined. HOMA2‐IR and HOMA2‐B are calculated by C‐peptide immunoreactivity and fasting blood glucose . The six clinical parameters (age, body mass index [BMI], hemoglobin A1c [HbA1c], homeostatic model assessment 2 estimates of insulin resistance [HOMA2‐IR], homeostatic model assessment 2 estimates of β‐cell function[HOMA2‐B] and glutamic acid decarboxylase antibodies [GADA]) are used in the cluster analysis. All the GADA‐positive patients are assigned to the severe autoimmune diabetes (SAID; cluster 1). The colors assigned to each cluster are consistent across the box‐and‐whisker plots. MARD, mild age‐related diabetes; MOD, mild obesity‐related diabetes; SIDD, severe insulin‐deficient diabetes; SIRD, severe insulin‐resistant diabetes.
Figure 2Hemoglobin A1c (HbA1c) trend after initiation of the educational program. The change in HbA1c levels after the educational program are compared (a) among clusters and (b) between severe insulin‐deficient diabetes (SIDD) and the other clusters. The x‐axis represents the follow‐up period. The y‐axis represents the HbA1c value (upper panel) and the average rate of change in HbA1c (lower panel), calculated by dividing the HbA1c value by that at baseline. This curvilinear graph uses a generalized additive model, where the gray zone is defined as a 95% confidence level interval (n = 651). HOMA2‐B, homeostatic model assessment 2 estimates of β‐cell function; HOMA2‐IR, homeostatic model assessment 2 estimates of insulin resistance; MARD, mild age‐related diabetes; MOD, mild obesity‐related diabetes; SAID, severe autoimmune diabetes; SIRD, severe insulin‐resistant diabetes.
Figure 3Differences of re‐admission risk for the educational program among the clusters. The Kaplan–Meier curve was used to show the probability of no second admission for the same program from the end of the first educational program. We compared cluster 2 with the other clusters (both mainly including type 2 diabetes). We adjusted for age at the first admission, sex, hemoglobin A1c and estimated glomerular filtration rate using the Cox regression model (P = 0.08). As the number of censored cases increases after 2 years, the figure is presented for 2 years (shown for the entire period in Figure S4). MARD, mild age‐related diabetes; MOD, mild obesity‐related diabetes; SIDD, severe insulin‐deficient diabetes; SIRD, severe insulin‐resistant diabetes.